What we know about AstraZeneca’s head-scratching vaccine results

AstraZeneca COVID vaccine up to 90% effective, data shows

These results show that the test vaccine is between 70% and 90% effective in stopping COVID-19, depending on the vaccine doses administered. For instance, of the 43,661 volunteers in Pfizer-BioNTech's vaccine candidate, 170 people tested Covid-19 positive and showed its symptoms. "Once the vaccine is indeed proven as safe and effective, every member state will receive it at the same time on a pro rata basis", von der Leyen said.

"The bulk of the vaccine rollout programme will be in January, February, March". Now I am coordinating a large crowd-sourced worldwide effort to better understand the scope and severity of COVID-19 in cancer patients. Combining the data from the two arms of the trial produced an overall efficacy for the vaccine of 70 percent. That rate actually includes data from two different approaches to dosing, including one where two full strength does were applied, which was 62% effective, and a much more promising dosage trial which used one half-dose and one full strength dose to follow - that one was 90% effective.

The Phase 3 trial for the Oxford vaccine included 24,000 participants, and it's expected to grow to 60,000 by the end of the year.

AstraZeneca will now seek approval from the FDA to also evaluate the half-dose protocol in the ongoing US trial. No serious safety events have been confirmed after a temporary pause in trials in September to investigate a potential issue.

Genetic material encoding the spike protein, which enables to infect human cells, is inserted into a modified cold virus from chimps.

A researcher in a laboratory at the Jenner Institute in Oxford, England, works on the coronavirus vaccine developed by AstraZeneca and Oxford University.

A vaccine works as a primer to train the immune system against a pathogen.

"A vaccine against the coronavirus disease will be available very soon in our country". But these methods can take decades to develop new vaccines.

In contrast, Pfizer's vaccine costs about $20 a dose, while Moderna's is upwards of $25. The virus is further modified to ensure that this chimp virus can not grow in people.

AstraZeneca COVID vaccine up to 90% effective, data shows

A vial of the coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England.

"The advantage of this vaccine is that it can be stored in the ordinary refrigerator temperatures of 2 to 8 degrees [Celsius; 36-46 degrees Fahrenheit] and is stable at that temperature and that, of course, has huge logistical advantages for transporting and delivering this vaccine to cities and towns and villages and rural areas around the world", Swaminathan said.

The competing mRNA vaccines by Moderna and Pfizer/BioNTech require ultracold temperatures for stability. Normal studies only have about 5,000 people in them before a vaccine is approved.

AstraZeneca alsosaid it will also seek an "Emergency Use Listing" from the World Health Organization in order to pursue an accelerated pathway to vaccines for low-income countries.

AstraZeneca's announcement comes on the heels of two major announcements from US companies, Pfizer and Moderna, about their progress in developing vaccines.

However, like all other candidate vaccines for COVID-19, AstraZeneca's vaccine is also lacking in key details such as the breakdown in infections, the durability, or the efficacy in the different age groups of trial participants.

"We know the COVID-19 vaccine will likely be distributed to local jurisdictions in phases and distribution will be targeted, at the beginning, to those who are most at risk", said Public Health Administrator Lisa Gonzalez with the DeKalb County Health Department. So it is hard to fully assess the differences between them.

The WHO's Director-General Tedros Adhanom Ghebreyesus said the urgency for vaccine development must be matched by the same urgency for fair distribution. "As long as it's done in a sensible way, there are plenty of issues the USA could work on with China that will suit both of their interests."Blinken would be likely to bring Washington back to its post-war worldwide strategy of advancing American interests by maintaining a world order that is favourable to the U.S. - which would mean a more predictable China policy than under Trump, he said.Lu Xiang, a U.S. affairs specialist with the Chinese Academy of Social Sciences, said Blinken as secretary of state would be a positive move for Beijing."With his experience, Biden is likely to make some important decisions on foreign policy", Lu said". We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article.

Related:

Comments


Other news